March 1: Tata Institute of Fundamental Research (TIFR) has unveiled a novel medicine – a pro-oxidant tablet in the fight against cancer. The tablet also diminishes the overall side effects of cancer treatment by approximately 50%.
The institute’s pioneering pro-oxidant Tablet Against Cancer Recurrence, named R+Cu, combines resveratrol and copper. This innovative tablet aims to aid cancer prevention by inhibiting the recurrence of this deadly disease.
This tablet is the outcome of over a decade of dedicated research at the Tata Memorial Centre, scientists have successfully formulated this cutting-edge tablet. Priced at approximately Rs100 ($1.2), the R+Cu tablet is set to make a significant impact in the field of oncology.
According to reports from NDTV, this new advancement holds immense promise in the battle against cancer. The pro-oxidant tablet has shown a 30% effectiveness in preventing cancer.
The tablet against cancer recurrence claims to diminish the overall side effects of cancer treatment by approximately 50%
The research conducted at the TIFR has shed light on the role of cell-free chromatin particles (cfChPs) in triggering cancer development within healthy cells. These remnants of cancer cells have been identified as key instigators of tumor formation, emphasizing the critical need for targeted interventions. Upon ingestion, the R+Cu tablet initiates the production of oxygen radicals within the stomach.
These radicals swiftly enter the bloodstream, where they specifically target and eliminate cfChPs. By disrupting this process, the tablet effectively impedes metastasis—the dangerous spread of cancer cells to other parts of the body.
